| 货号 | 5559S |
| 反应种属 | Human/Mouse/Rat |
| 来源宿主 | Rabbit |
| 应用 | W/IP |
| 目标/特异性 | LRRK2 Antibody detects endogenous levels of total LRRK2 protein. |
| 使用方法 | WB(1:1000) IP (1:50) |
| 供应商 | CST |
| 背景 | Parkinson’s disease (PD), the second most common neurodegenerative disease after Alzheimer’s, is a progressive movement disorder characterized by rigidity, tremors, and postural instability. The pathological hallmark of PD is progressive loss of dopaminergic neurons in the substantia nigra of the ventral midbrain and the presence of intracellular Lewy bodies (protein aggregates of α-synuclein, ubiquitin, and other components) in surviving neurons of the brain stem (1). Various genes and loci (α-synuclein/PARK1 and 4, parkin/PARK2, UCH-L1/PARK5, PINK1/PARK6, DJ-1/PARK7, LRRK2/PARK8, synphilin-1, and NR4A2) are genetically linked to PD (2). Leucine-rich repeat kinase 2 (LRRK2) contains amino-terminal leucine-rich repeats (LRR), a Ras-like small GTP binding protein-like (ROC) domain, an MLK protein kinase domain, and a carboxy-terminal WD40 repeat domain. At least 20 LRRK2 mutations have been linked to PD-the G2019S mutation being the most prevalent (3). The G2019S mutation causes increased LRRK2 kinase activity, which induces a progressive reduction in neurite length, leading to progressive neurite loss and decreased neuronal survival (4). The MLK inhibitor CEP-1347 is being tested in PD clinical trials, indicating the potential value of LRRK2 as a therapeutic target for treatment of PD (5). |
| 存放说明 | -20C |
| 计算分子量 | 290 |
Western blot analysis of extracts from mouse LRRK2-/- and wild-type tissue using LRRK2 Antibody (upper) and TrkB (80E3) Rabbit mAb #4603 (lower). (Mouse wild-type and LRRK2-/- brains were kindly provided by Dr. Jie Shen, Brigham and Womens Hospital and Harvard Medical School, Boston, MA). Western blot分析小鼠LRRK2 -/-或野生型组织提取物，使用的抗体是LRRK2 Antibody 兔多抗（上图）或TrkB (80E3) Rabbit mAb 兔单抗 #4603（下图）。（小鼠野生型和LRRK2 -/-大脑由 Brigham and Womens Hospital and Harvard Medical School, Boston, MA的Dr. Jie Shen提供） |
